Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

The FDA approved Bosaya and Aukelso, biosimilars of Prolia and Xgeva, respectively, for the treatment of solid tumors, like ...

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

USFDA approved affordable biosimilars Bosaya and Aukelso approved by Biocon Biologics Ltd, offering treatment options for ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (FDA) ...

CHMP recommends AVT03 biosimilar for marketing authorization in the EU and UK by the European Commission and MHRA.

On February 13, 2025, the FDA approved Samsung Bioepis Co., Ltd.’s denosumab biosimilars, OSPOMYV™ (denosumab-dssb; 60 mg pre-filled syringe) and XBRYK™ (denosumab-dssb; 120 mg vial), referencing ...

EMA recommends marketing authorization for AVT03, a biosimilar of Amgen's Prolia and Xgeva, by Dr. Reddy's Laboratories.

Shares of the company ended 1.6% lower at a price of ₹354.40 on the BSE. Last week's losses have dragged the stock 4% lower ...

Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen’s bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors ...

Fresenius announced today that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States. This press ...

Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S.